Medication info
Keglitto Tablet 10/5 mg (Empagliflozin, Linagliptin benzenesulfonate)

Keglitto Tablet 10/5 mg (Empagliflozin, Linagliptin benzenesulfonate)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›10mg / 1 tabletLinagliptin Besylate›6.67mg / 1 tablet
Manufacturer / importer
Kyungbo Pharmaceutical Co., Ltd.
Appearance
Flat on both sides with sharp edges, light yellow triangular film-coated tablet
Packaging
10 tablets/PTP, 30 tablets/PTP [(10 tablets/PTP × 3)]
Approval status
Active

MFDS item code 202503049 · Approved 2025.11.21

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended starting dose of this medicine is empagliflozin 10 mg/linagliptin 5 mg (equivalent to 6.67mg of linagliptin besylate) once daily. For patients who tolerate empagliflozin 10 mg/linagliptin 5 mg but require additional glycemic control, the dose of this medicine may be increased to 25/5 mg (equivalent to 6.67mg of linagliptin besylate) once daily. Patients switching from combination therapy with empagliflozin and linagliptin to this medicine should receive the same doses they were previously taking. This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. However, if it is within 12 hours of the next dose, skip the missed dose and take the next dose at the usual scheduled time. Do not take a double dose in one day. Special populations Patients with renal impairment This medicine is not recommended to improve glycemic control in patients with an estimated glomerular filtration rate (eGFR) below 45 ml/min/1.73m2. No dose adjustment is necessary in patients with an estimated glomerular filtration rate of 45 ml/min/1.73m2 or higher. Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. Older adults No dose adjustment is necessary based on age. In patients aged 75 years or older, renal function and the risk of volume depletion should be taken into consideration.

Ingredients

Manufacturer
Kyungbo Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used in conjunction with dietary and exercise therapy to assist patients with type 2 diabetes in managing their blood sugar levels. The combination of empagliflozin and linagliptin effectively helps to control blood sugar, aiding in the treatment of diabetes. Therefore, it is used to improve blood sugar control.

How to take

Adult dose

The recommended starting dose of this medicine is empagliflozin 10 mg/linagliptin 5 mg (equivalent to 6.67mg of linagliptin besylate) once daily. For patients who tolerate empagliflozin 10 mg/linagliptin 5 mg but require additional glycemic control, the dose of this medicine may be increased to 25/5 mg (equivalent to 6.67mg of linagliptin besylate) once daily. Patients switching from combination therapy with empagliflozin and linagliptin to this medicine should receive the same doses they were previously taking. This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. However, if it is within 12 hours of the next dose, skip the missed dose and take the next dose at the usual scheduled time. Do not take a double dose in one day. Special populations Patients with renal impairment This medicine is not recommended to improve glycemic control in patients with an estimated glomerular filtration rate (eGFR) below 45 ml/min/1.73m2. No dose adjustment is necessary in patients with an estimated glomerular filtration rate of 45 ml/min/1.73m2 or higher. Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. Older adults No dose adjustment is necessary based on age. In patients aged 75 years or older, renal function and the risk of volume depletion should be taken into consideration.

Precautions

This medication is composed of two components, empagliflozin and linagliptin. This medication should not be administered to certain patients. For example, individuals with allergies to any component of this medication, those with type 1 diabetes, diabetic ketoacidosis, or patients undergoing dialysis should not take this medication. It should be used with caution in patients with impaired kidney function or those with heart failure. The effectiveness of this medication depends on kidney function, so regular monitoring of kidney function before and during treatment is important. Rare adverse reactions such as acute pancreatitis or blistering dermatitis may occur, so if abdominal pain or skin abnormalities arise while taking this medication, it is essential to consult a doctor immediately. The most common side effect reported is urinary tract infection, along with hypoglycemia, ketoacidosis, and hypersensitivity reactions. Caution should be exercised when taken with insulin or sulfonylureas as the risk of hypoglycemia may be increased. This medication may lower blood pressure, so patients who are at risk for hypotension or dehydration should be monitored closely for their fluid status while taking it. Additionally, the risk of genital fungal infections may be increased, so appropriate treatment should be sought if relevant symptoms occur. Elderly patients aged 75 and older have a higher risk of fluid loss and should take this medication with extra caution. Pregnant or breastfeeding women are advised to avoid taking this medication, especially during breastfeeding, where it is recommended to discontinue the use of this medication. The safety and efficacy of this medication have not been established for children under 18 years of age, so it is advisable not to use it in this population. In cases of overdose, appropriate measures such as removing the medication from the gastrointestinal tract are necessary. There is not much experience with overdose, but caution is required. While taking this medication, there is a risk of hypoglycemia when driving or operating machinery, particularly when taken with insulin or sulfonylureas, so caution is advised. Finally, this medication should be stored out of reach of children and kept in its original container to maintain its quality.

Side effects

  • Urinary tract infection
  • vulvovaginitis
  • vulvitis
  • balanitis
  • genital infection
  • hypersensitivity
  • angioedema
  • urticaria
  • hypoglycemia
  • thirst
Show 156 more
  • ketoacidosis
  • cough
  • constipation
  • pancreatitis
  • oral ulcer formation
  • pruritus
  • rash
  • blistering like pemphigus
  • rhabdomyolysis
  • fluid volume depletion
  • increased urination
  • urination difficulty
  • interstitial nephritis
  • increased amylase
  • increased lipase
  • increased hematocrit
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • upper abdominal pain
  • enterocolitis
  • bowel obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disorder
  • Alzheimer’s dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • death
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • stomach cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • constipation
  • upper abdominal pain
  • dyspepsia
  • vomiting
  • gastritis
  • anxiety
  • depression
  • insomnia
  • headache
  • dizziness
  • drowsiness
  • arthralgia
  • osteoporosis
  • musculoskeletal discomfort
  • myositis
  • myalgia
  • soft tissue mass
  • rotator cuff syndrome
  • benign prostatic hyperplasia
  • erectile dysfunction
  • thyroid gland enlargement
  • anemia
  • lymphadenopathy
  • vulvar pruritus
  • genital pruritus
  • dyslipidemia
  • weight loss
  • itching
  • insomnia
  • sleep disorders
  • hypertension
  • vertigo
  • ear pain
  • positional vertigo
  • vascular stent stenosis
  • vascular stent thrombosis
  • vascular disorders
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular disorders
  • peripheral artery occlusive disease
  • benign ovarian tumor
  • bladder cancer
  • cholesteatoma
  • leiomyoma
  • autoimmune hepatitis
  • cholelithiasis
  • hepatitis
  • ear pain
  • positional vertigo
  • headache
  • drowsiness
  • facial paralysis
  • memory impairment
  • neuralgia
  • Parkinsonism
  • polyneuropathy
  • sensory disturbances
  • CNS-origin vertigo
  • peripheral edema
  • facial swelling
  • peripheral swelling
  • chills
  • abnormal sensations
  • edema
  • pain
  • puncture site pain
  • vascular stent stenosis
  • vascular stent thrombosis
  • chest pain
  • fatigue
  • peripheral swelling
  • facial swelling
  • edema
  • contusion
  • bone contusion
  • concussion
  • laceration
  • rib fracture
  • corneal abrasion
  • fall
  • hand fracture
  • iliotibial band syndrome
  • open globe injury
  • pelvic fracture
  • road traffic accident
  • splenic injury
  • sternum fracture

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a closed container to protect it from air and moisture, and ideally at room temperature between 1 and 30 degrees Celsius. By storing it this way, the efficacy of the medication can be maintained and it can be used safely.

Appearance and packaging

Appearance

Flat on both sides with sharp edges, light yellow triangular film-coated tablet

Package unit

10 tablets/PTP, 30 tablets/PTP [(10 tablets/PTP × 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.